<DOC>
	<DOCNO>NCT00343486</DOCNO>
	<brief_summary>This study test effectiveness safety two dos solabegron placebo reduce symptom overactive bladder .</brief_summary>
	<brief_title>Dose Ranging Study Of Solabegron Versus Placebo In Female Patients With Overactive Bladder Symptoms</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Solabegron</mesh_term>
	<criteria>Overactive bladder symptom urgency urge incontinence frequency may associate nocturia without bladder pain . Body mass index range = 19 kg/m2 &lt; 35 kg/m2 . Pregnant Of childbearing potential willing use specific barrier method outline protocol . Grade III/IV pelvic organ prolapse without cystocele . History interstitial cystitis bladder relate pain . Stress incontinence mix incontinence stress incontinence predominant component base prior history . History pelvic prolapse repair ( cystocele rectocele ) urethral diverticulectomy within six month screen . Urinary incontinence due cause detrusor activity ( e.g. , overflow incontinence ) . Nocturnal enuresis . Urinary retention , evidence poor detrusor function . Current history Urinary Tract Infection . Diabetes insipidus . History myocardial infarction , unstable angina , Congestive heart failure . Chronic severe constipation . History prior antiincontinence surgery . History radiation cystitis history pelvic irradiation . Electrostimulation , biofeedback , bladder training therapy ( behavioral therapy ) previous month prior screening , intention initiate therapy study . Pessaries implant also exclude . Received investigational product within 30 day enrollment study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Overactive Bladder</keyword>
</DOC>